A watchdog has endorsed a new scheme under which a bone marrow-cancer drug’s manufacturers would refund the NHS if a patient did not respond to treatment. The National Institute for Health and Clinical Excellence is recommending multiple myeloma patients in Wales and England should get Velcade on the NHS.
